Bio


Medical degree at CES University, Medellin - Colombia (2010-2016)

Cardiac surgery and critical care residency at Leipzig Heart Center, Leipzig - Germany (2017 to the present)

Doctoral degree at Leipzig University School of Medicine, Leipzig - Germany (2020)

Postdoctoral research fellowship at Cardiothoracic Surgery Department Stanford Universitiy School of Medicine, Stanford, California - USA (2020-2021)

Member of the Board of Directors of the Latin American Association of Cardiac and Endovascular Surgery - LACES (Since 10/2020)

Chair of the Residents Committee of the Latin American Association of Cardiac and Endovascular Surgery - LACES (Since 11/2020)

Associate editor at the Latin American Association of Cardiac and Endovascular Surgery - LACES (Since 03/2021)


Clinical interests:

Mitral Valve Surgery
Coronary Revascularization
Thoracic Aortic Surgery
Heart Transplantation
Tricuspid Valve Surgery
Minimally Invasive Surgery
Transcatheter Valve Therapy
Ventricular Assist Devices
Extracorporeal Life Support

Boards, Advisory Committees, Professional Organizations


  • Board member, Latin American Association of Cardiac and Endovascular Surgery (LACES) (2020 - Present)
  • Trainee member, German Society for Thoracic and Cardiovascular Surgery (DGTHG) (2018 - Present)
  • Trainee member, The Society of Thoracic Surgeons (STS) (2018 - Present)
  • Trainee member, European Association for Cardio-Thoracic Surgery (EACTS) (2018 - Present)

Professional Education


  • M.D., CES University, Medellin-Colombia, Medicine (2016)
  • M.D., The State Chamber of Physicians of Saxony - Germany, German medical license (2017)
  • Ph.D., Leipzig University School of Medicine, Germany, German "Promotion". Cardiac Surgery; Mitral valve (2020)

Stanford Advisors


Community and International Work


  • LACES

    Topic

    Cardiac and endovascular Surgery

    Populations Served

    Latin America

    Location

    International

    Ongoing Project

    Yes

    Opportunities for Student Involvement

    Yes

Current Research and Scholarly Interests


Secondary mitral valve regurgitation
Mitral valve biomechanics
Prosthetic valve degeneration after mitral valve replacement
Mitral valve patient-prosthesis mismatch
Off-pump coronary revascularization
Metabolic syndrome and MIDCAB
Coronary Artery Bypass Grafting (CABG) for ST- Elevation Myocardial Infarction (STEMI)
Extracorporeal Life Support in cardiac surgery
Tricuspid valve repair for tricuspid regurgitation during Left Ventricular Assist Device (LVAD) implantation

Graduate and Fellowship Programs


All Publications


  • The Latinamerican Association of Cardiac and Endovascular Surgery Statement regarding the recently released 2020 ACC/AHA Guidelines for the Management of Patients with Valvular Heart Disease. The Annals of thoracic surgery Dayan, V., Garcia-Villarreal, O. A., Escobar, A., Ferrari, J., Quintana, E., Marin-Cuartas, M., Almeida, R. 2021

    View details for DOI 10.1016/j.athoracsur.2021.02.001

    View details for PubMedID 33581157

  • 30-Day perioperative mortality following venoarterial extracorporeal membrane oxygenation for postcardiotomy cardiogenic shock in patients with normal preoperative ejection fraction Interact Cardiovasc Thorac Surg Menon, P., Flo-Forner, A., Marin-Cuartas, M., Lehmann, S., Saeed, D., Ginther, A., Borger, M. A., Ender, J. 2021

    View details for DOI 10.1093/icvts/ivaa323

  • Mid-term results after isolated tricuspid valve surgery in the presence of right ventricular leads. The Journal of cardiovascular surgery Pfannmueller, B. n., Budde, L. M., Etz, C. D., Noack, T. n., Cuartas, M. M., Misfeld, M. n., Borger, M. A. 2021

    Abstract

    Patients with tricuspid valve (TV) disease and indication for TV surgery frequently have permanent pacemaker (PM) or defibrillator (AICD) leads, placed in the right ventricle (RV). The aim of this study was to analyse postoperative results and mid-term outcomes after isolated TV surgery (with no further concomitant cardiac procedures) in the presence of permanent RV leads.From January 2005 to January 2019 a total of 80 patients (mean age: 67.7±10.3 yrs; 56.3% male) with isolated TV disease and presence of at least one permanent RV lead in place were referred to our institution for isolated TV repair / replacement; patients with concomitant procedures were excluded for this analysis. All data were retrospectively analysed. The follow-up was 98% complete.Mean follow-up time was 4.3±3.9 years. Mean preoperative clinical NYHA status was 3.0±0.8, left ventricular ejection fraction 50.7±12.9%, mean pulmonary artery pressure 23.8±9.3mmHg, creatinine 125.7±57.5μmol/l, mean MELD-XI Score (Model of Endstage-Liver Disease excluding INR) was 14.6±5.0 μmol/l. Thirty-day mortality was 6.3% with a 5-years survival of 58.2±6.0%. Cox regression analysis revealed the MELD-XIScore as the only highly significant predictor for postoperative mortality (p=0.002).In conclusion, Hepatorenal dysfunction-possibly indicating long lasting TV failure- could be a factor for limited postoperative survival in our patient cohort. This finding could unterline our hypothesis, that early TV surgery may achieve better postoperative survival, even in patients with TV disease caused by RV leads. Further investigations are needed.

    View details for DOI 10.23736/S0021-9509.21.11803-8

    View details for PubMedID 33829746

  • Postoperative outcome after reoperative isolated tricuspid valve surgery-is there a predictor for survival? European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery Pfannmueller, B. n., Budde, L. M., Etz, C. D., Noack, T. n., Cuartas, M. M., Misfeld, M. n., Borger, M. A. 2021

    Abstract

    Reoperative tricuspid valve (TV) surgery is considered high risk even in the absence of additional concomitant cardiac procedures. The purpose of this study was to evaluate preoperative clinical parameters as predictors for survival after isolated reoperative TV surgery.From January 2005 to January 2019, 85 patients (mean age: 66.7 ± 10.3 years, 34 male) with severe isolated TV regurgitation and prior cardiac surgery were referred to our centre for elective or urgent TV repair/replacement; patients with endocarditis were excluded. We retrospectively analysed preoperative hepatorenal function [reflected by widely used clinical and laboratory parameters and the Model of End-stage-Liver Disease excluding International Normalized Ratio (MELD-XI) score] as a predictor for postoperative survival.At hospital admission, the patients' average preoperative New York Heart Association class was 2.9 ± 0.6, left ventricular ejection fraction 52.5 ± 10.6%, mean pulmonary artery pressure 24.7 ± 8.0 mmHg, creatinine 115.4 ± 66.6 μmol/l, bilirubin 20.0 ± 19.6 μmol/l and the mean MELD-XI score was 13.3 ± 4.0 μmol/l. The mean follow-up was 5.4 ± 4.2 years. Thirty-day mortality was 5%, 5-year survival was 60.6 ± 5.4% and 10-year survival was 42.9 ± 6.5%. The multivariable Cox regression analysis evaluated the MELD-XI score [hazard ratio (HR 1.144, confidence interval 95% 1.0-1.3, P = 0.005] and diabetes mellitus (HR 2.27, confidence interval 95% 1.0-5.0, P = 0.04) as significant predictors for excess mortality while age and mean pulmonary artery pressure did not reliably predict clinical outcome.Hepatorenal dysfunction was one main factor accounting for limited postoperative survival in our patient cohort. The MELD-XI score is easy to calculate and seems to reliably predict the perioperative risk in patients with prior cardiac surgery and indication for TV surgery.

    View details for DOI 10.1093/ejcts/ezab134

    View details for PubMedID 33769458

  • Declaración de la Latin American Association of Cardiac and Endovascular Surgery (LACES) sobre las guías de recomendación clínica de la AHA/ACC para el tratamiento de pacientes con valvulopatía 2020 Cirugia Cardiovascular Dayan, V., Garcia-Villareal, O. A., Escobar, A., Ferrari, J., Quintana, E., Marin-Cuartas, M., Almeida, R. 2021; 28 (2): 64-66
  • The Latin American Association of Cardiac and Endovascular Surgery statement regarding the recently released 2020 ACC/AHA Guidelines for the Management of Patients with Valvular Heart Disease Braz J Cardiovasc Surg Dayan, V., Garcia-Villareal, O. A., Escobar, A., Ferrari, J., Quintana, E., Marin-Cuartas, M., Almeida, R. M. 2021; 36 (2): 275-7
  • Perspective MICS-CABG Operative Techniques in Coronary Artery Bypass Surgery Marin-Cuartas, M., Davierwala, P. M. Springer. 2021: 205–234
  • Reply to Tourmousoglou. European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery Marin-Cuartas, M. n., Davierwala, P. M. 2021

    View details for DOI 10.1093/ejcts/ezab011

    View details for PubMedID 33501932

  • The Latin American Association of Cardiac and Endovascular Surgery statement regarding the recently released 2020 ACC/AHA Guidelines for the Management of Patients with Valvular Heart Disease. European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery Dayan, V. n., Garcia-Villarreal, O. A., Escobar, A. n., Ferrari, J. n., Quintana, E. n., Marin-Cuartas, M. n., Almeida, R. n. 2021

    View details for DOI 10.1093/ejcts/ezab027

    View details for PubMedID 33576782

  • Annuloplasty ring dehiscence after mitral valve repair: incidence, localization and reoperation Noack, T., Kiefer, P., Vivell, N., Sieg, F., Marin-Cuartas, M., Leontyev, S., Holzhey, D., Garbade, J., Pfannmueller, B., Davierwala, P., Misfeld, M., Seeburger, J., Borger, M. OXFORD UNIV PRESS INC. 2020: 300–307

    Abstract

    Mitral valve (MV) annuloplasty ring dehiscence with subsequent recurrent mitral regurgitation represents an unusual but challenging clinical problem. Incidence, localization and outcomes for this complication have not been well defined.From 1996 to 2016, a total of 3478 patients underwent isolated MV repair with ring annuloplasty at the Leipzig Heart Centre. Of these patients, 57 (1.6%) underwent reoperation due to annuloplasty ring dehiscence. Echocardiographic data, operative and early postoperative characteristics as well as short- and long-term survival rates after MV reoperation were analysed.Occurrences of ring dehiscence were acute (<30 days), early (≤1 year) and late (>1 year) in 44%, 33% and 23% of patients, respectively. Localization of annuloplasty ring dehiscence was found most frequently in the P3 segment (68%), followed by the P2 (51%) and the P1 segments (47%). The 30-day mortality rate and 1- and 5-year survival rates after MV reoperation were 2%, 89% and 74%, respectively. During reoperation, MV replacement was performed in 38 (67%) and MV re-repair in 19 (33%) patients.Annuloplasty ring dehiscence is clinically less common, localized more frequently on the posterior annulus and occurs mostly acutely or early after MV repair. MV reoperation can be performed safely in such patients.

    View details for DOI 10.1093/ejcts/ezz219

    View details for Web of Science ID 000515105300009

    View details for PubMedID 31369069

  • Commentary: Does only the practice make the master? The Journal of thoracic and cardiovascular surgery Marin-Cuartas, M. n., Dayan, V. n. 2020

    View details for DOI 10.1016/j.jtcvs.2020.12.012

    View details for PubMedID 33468330

  • Aktuelles zur Herzklappenchirurgie Marin-Cuartas, M., Borger, M. A. Herzmedizin. 2020
  • Aortic Valve-Sparing Root Replacement. Cardiac Surgery- A Complete Guide Marin-Cuartas, M., Borger, M. A. Springer Nature. 2020: 315–324
  • Minimally invasive mitral valve repair INDIAN JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY Cuartas, M., Davierwala, P. 2020; 36: 44–52
  • Transcatheter “valve‐in‐valve” mitral valve replacement for patient‐prosthesis mismatch: Chronicle of a death foretold. Marin-Cuartas, M., Noack, T., Kiefer, P., Borger, M. A. J Card Surg. https://doi.org/10.1111/jocs.15050. 2020
  • Minimally Invasive Mitral Valve Surgery Cardiac Surgery- A Complete Guide Marin-Cuartas, M., Davierwala, P. M. Springer Nature. 2020: 429–436
  • Five-year outcomes following complex reconstructive surgery for infective endocarditis involving the intervalvular fibrous body. European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery Davierwala, P. M., Marin-Cuartas, M. n., Misfeld, M. n., Deo, S. V., Lehmann, S. n., Garbade, J. n., Holzhey, D. M., Borger, M. A., Bakhtiary, F. n. 2020

    Abstract

    Destruction of the intervalvular fibrous body (IFB) due to infective endocarditis (IE) warrants a complex operation involving radical debridement of all infected tissue, followed by double valve replacement (aortic and mitral valve replacement) with patch reconstruction of the IFB. This study assesses the 5-year outcomes in patients undergoing this complex procedure for treatment of double valve IE with IFB involvement.A total of 127 consecutive patients underwent double valve replacement with reconstruction of the IFB for active complex IE between January 1999 and December 2018. Primary outcomes were 3-year and 5-year survival, as well as 5-year freedom from reoperation.Patients' mean age was 65.3 ± 12.9 years. Preoperative cardiogenic shock and sepsis were present in 17.3% and 18.9%, respectively. The majority of patients (81.3%) had undergone previous cardiac surgery. Overall, 30-day and 90-day mortality rates were 28.3% and 37.0%, respectively. The 3- and 5-year survival rates for all patients were 45.3 ± 5.1% and 41.8 ± 5.8%, and for those who survived the first 90 postoperative days 75.8 ± 6.1% and 70.0 ± 8.0%, respectively. The overall 5-year freedom from reoperation was 85.1 ± 5.7%. Preoperative predictors for 30-day mortality were Staphylococcus aureus [odds ratio (OR) 1.65; P = 0.04] and left ventricular ejection fraction (LVEF) <35% (OR 12.06; P = 0.03), for 90-day mortality acute kidney injury requiring dialysis (OR 6.2; P = 0.02) and LVEF <35% (OR 9.66; P = 0.03) and for long-term mortality cardiogenic shock (hazard ratio 2.46; P = 0.01).Double valve replacement with reconstruction of the IFB in patients with complex IE is a challenging operation associated with high morbidity and mortality, particularly in the first 90 days after surgery. Survival and freedom from reoperation rates are acceptable thereafter, particularly considering the severity of disease and complex surgery.

    View details for DOI 10.1093/ejcts/ezaa146

    View details for PubMedID 32380545

  • Dynamic mitral valve geometry in patients with primary and secondary mitral regurgitation: implications for mitral valve repair Noack, T., Janietz, M., Lurz, P., Kiefer, P., Sieg, F., Marin-Cuartas, M., Spampinato, R., Besler, C., Rommel, K., Holzhey, D., Mohr, F., Ender, J., Borger, M., Seeburger, J. OXFORD UNIV PRESS INC. 2019: 983–92

    Abstract

    The goal of this study was to quantify the mitral valve (MV) annulus, the MV shape and the anatomical MV orifice area throughout the cardiac cycle using 4-dimensional MV analysis software in patients with primary mitral regurgitation (PMR) and secondary mitral regurgitation (SMR) in comparison to a healthy control group.Three-dimensional transoesophageal echocardiograms of the MV were acquired for 29 patients with PMR, for 28 patients with SMR and for 18 healthy control subjects. The MV was quantified with regards to anterior-posterior and lateromedial diameter, annular area and circumference, intertrigonal (IT) distance, annular sphericity index, annular height to commissural width ration, and anatomical MV orifice area throughout the cardiac cycle using 3-dimensional transoesophageal echocardiography-based 4-dimensional MV advanced analysis software.Normal annulus dynamics display a systolic enlargement followed by an early-diastolic plateau phase and a late-diastolic contraction. The IT distance showed a linear association with the anterior-posterior diameter (= 1.11 × IT distance) and lateromedial diameter (= 1.44 × IT distance) in the control subjects. Mitral regurgitation is associated with a less dynamic, planar and dilated annulus with small variations between PMR and SMR. The IT distance was less affected by mitral regurgitation compared to the control subjects.The novel 4-dimensional MV analysis allows new insights into the dynamic MV geometry in patients with PMR and SMR compared to the control subjects. The IT distance may be used to predict annuloplasty ring sizing.

    View details for DOI 10.1093/ejcts/ezz096

    View details for Web of Science ID 000493091500021

    View details for PubMedID 30932164

  • The value of an "Endocarditis Team" ANNALS OF CARDIOTHORACIC SURGERY Davierwala, P. M., Marin-Cuartas, M., Misfeld, M., Borger, M. A. 2019; 8 (6): 621–29

    Abstract

    Establishment of the Heart Team concept in the field of cardiovascular medicine has resulted in quality improvement in the management of heart valve disease and heart failure. Similarly, the concept of an Endocarditis Team would be important in improving outcomes in patients with infective endocarditis (IE), given it is an uncommon clinical entity with general practitioners and low-volume centers lacking sufficient experience in its management. A multidisciplinary approach can substantially reduce the still unacceptably high morbidity and mortality in patients with IE, as it allows early diagnosis and appropriate comprehensive management. Decision-making within the Endocarditis Team must follow a standard protocol that is based on current clinical guidelines for the management of IE. If surgery is indicated, it is best performed sooner than later in most instances. Communication between referring hospitals and reference centers with an established Endocarditis Team must be smooth and definite protocols for transfer to experienced endocarditis centers with surgical facilities is essential. Follow-up and outpatient care following hospital discharge is crucial due to the possibility of residual infection and risk of development of recurrent endocarditis or heart failure, particularly within the first 2 years. Patient and health-care provider education is the mainstay for the accurate implementation of the Endocarditis Team concept. The following Keynote Lecture offers an overview of the current literature supporting the multidisciplinary management of IE and addresses multiple aspects related to the Endocarditis Team, highlighting its importance and necessity for the comprehensive treatment of this complex disease.

    View details for DOI 10.21037/acs.2019.09.03

    View details for Web of Science ID 000500370000004

    View details for PubMedID 31832352

    View details for PubMedCentralID PMC6892719

  • Tricuspid valve endocarditis ANNALS OF CARDIOTHORACIC SURGERY Marin-Cuartas, M., Misfeld, M., Borger, M. A., Pfannmuller, B. 2019; 8 (6): 708–10

    View details for DOI 10.21037/acs.2019.10.02

    View details for Web of Science ID 000500370000020

    View details for PubMedID 31832368

    View details for PubMedCentralID PMC6892727

  • Isolated Mitral Valve Repair in Patients with Reduced Left Ventricular Ejection Fraction ANNALS OF THORACIC AND CARDIOVASCULAR SURGERY Noack, T., Cuartas, M., Kiefer, P., Garbade, J., Pfannmueller, B., Seeburger, J., Borger, M. A. 2019; 25 (6): 326–35

    Abstract

    This study aims to analyze the clinical outcomes after isolated mitral valve (MV) repair in patients with reduced left ventricular ejection fraction (LVEF <50%) with focus on perioperative characteristics, survival, and freedom from reoperations.Between 1997 and 2015, 557 patients with reduced LVEF (age: 62.8 ± 11.7 years, male: 320) underwent MV repair for symptomatic mitral regurgitation (MR). Etiologies were dilated non-ischemic cardiomyopathy and ischemic cardiomyopathy in 487 (87.4%) and 70 (12.6%) patients, respectively; these were classified into three different subgroups: LVEF 40%-49% (group 1), 30%-39% (group 2), and <30% (group 3).Overall, 294, 145, and 118 patients had an LVEF of 40%-49%, 30%-39%, and <30%, respectively. Logistic EuroSCORE was significantly higher (P <0.001) as the LVEF worsened. The survival analysis for groups 1-3, respectively, revealed the following: 30-day mortality: 1.4%, 3.4%, and 7.6% (P <0.001); 1-year survival: 93.9%, 89.4%, and 82% (P <0.001); 5-year survival: 81.2%, 75.2%, and 58% (P <0.001).MV repair in patients with impaired LVEF could be performed safely with good clinical short- and mid-term outcome. Nevertheless, reduced preoperative LVEF correlates with worse perioperative and long-term survival.

    View details for DOI 10.5761/atcs.oa.19-00093

    View details for Web of Science ID 000503987600006

    View details for PubMedID 31588074

    View details for PubMedCentralID PMC6923726

  • Benefits of Mitral Valve Repair in STICH Patients: Time To Re-Evaluate a Much Maligned Therapy Option? Marin-Cuartas, M., Borger, M. A. Structural Heart. 2019
  • Minimally Invasive Cardiac Surgery Through Periareolar Approach CTSNet Marin Cuartas, M., Lizeth, S. D., Quintero, A. A., Jaramillo, J. S., Rendon, J. C. 2018

    View details for DOI 10.25373/ctsnet.6815693.

  • Mitral valve repair: Robotic and other minimally invasive approaches PROGRESS IN CARDIOVASCULAR DISEASES Cuartas, M., Javadikasgari, H., Pfannmueller, B., Seeburger, J., Gillinov, A., Suri, R. M., Borger, M. A. 2017; 60 (3): 394–404

    Abstract

    Robotic and minimally invasive mitral valve (MV) procedures have been performed with increasing frequency over time. These alternatives offer similar efficacy to that achieved via standard median sternotomy, particularly in large volume centers, along with low perioperative morbidity and mortality rates. Moreover, patient acceptance is oftentimes increased due to less postoperative pain and shorter recovery times, as well as superior cosmetic results. However, these techniques are technically complex and associated with a significant learning curve. The following review offers an overview of the most relevant aspects related to minimally invasive and robotic MV repair. Although these techniques are well established in referral centers, future innovations should concentrate on decreasing complexity and improving reproducibility of these procedures.

    View details for DOI 10.1016/j.pcad.2017.11.002

    View details for Web of Science ID 000424727800011

    View details for PubMedID 29128572

  • Redo Valve-Sparing Ascending Aorta and Total Arch Replacement in a Young Patient With Loeys-Dietz Syndrome: A Challenging Procedure Marin Cuartas, M., Rendon, J. C., Jaramillo, J. S. CTSNet. 2017
  • Single-stage Extra-anatomic Ascending-to-descending Aortic Bypass Graft Surgery for Repair of Atresia of the Aortic Arch. Escobar, A., Marin, M., Turizo, J., Meza, R. CTSNet. 2017